Equities

Semler Scientific Inc

Semler Scientific Inc

Actions
  • Price (EUR)67.00
  • Today's Change23.40 / 53.67%
  • Shares traded245.00
  • 1 Year change+103.03%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 14:51 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Semler Scientific, Inc. develops, manufactures, and markets products and services that assist in evaluating and treating chronic diseases. The Company provides technology solutions to healthcare providers. The Company's flagship product, QuantaFlo is a four-minute in-office blood flow test. Healthcare providers can use blood flow measurements as part of their examinations of a patient’s vascular condition, including assessments of patients who have vascular disease. QuantaFlo features a sensor clamp that is placed on the toe or finger. Infrared light emitted from the clamp on the dorsal surface of the digit is scattered and reflected by the red blood cells coursing through the area of illumination. Returning light is sensed by the sensor. A blood flow waveform is instantaneously constructed by its proprietary software algorithm. Its customers for QuantaFlo include insurance plans, physician groups, risk assessment groups, hospitals and retailers.

  • Revenue in USD (TTM)58.94m
  • Net income in USD15.91m
  • Incorporated2013
  • Employees92.00
  • Location
    Semler Scientific Inc2340-2348 Walsh Avenue, Suite 2344SANTA CLARA 95051United StatesUSA
  • Phone+1 (408) 627-4557
  • Fax+1 (302) 636-5454
  • Websitehttps://www.semlerscientific.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.